Current drug regimens for the treatment of intestinal helminth infections.
D000871:Anthelmintics / Q000627:therapeutic use*; D001196:Ascariasis / Q000188:drug therapy; D002590:Cestode Infections / Q000188:drug therapy; D006373:Helminthiasis / Q000188:drug therapy*; D006725:Hookworm Infections / Q000188:drug therapy; D006790:Host-Parasite Interactions; D006801:Humans; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy*; D007978:Levamisole / Q000627:therapeutic use; D008463:Mebendazole / Q000627:therapeutic use; D009534:Niclosamide / Q000627:therapeutic use; D010303:Paromomycin / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011715:Pyrantel / Q000627:therapeutic use; D011774:Pyrvinium Compounds / Q000627:therapeutic use; D011796:Quinacrine / Q000627:therapeutic use; D013322:Strongyloidiasis / Q000188:drug therapy; D013750:Tetrachloroethylene / Q000627:therapeutic use; D013827:Thiabendazole / Q000627:therapeutic use; D014257:Trichuriasis / Q000188:drug therapy
D000871:Anthelmintics; D010879:Piperazines; D011774:Pyrvinium Compounds; D007978:Levamisole; D011715:Pyrantel; D010303:Paromomycin; D008463:Mebendazole; D009534:Niclosamide; D011796:Quinacrine; D013827:Thiabendazole; D013750:Tetrachloroethylene